# Frequently Asked Questions

> FAQ — PT-141, Kisspeptin & Melanotan II | Pussy Peptide — Answers to common questions about PT-141 (bremelanotide), kisspeptin, and Melanotan II — mechanism, FDA status, and what the research actually shows.

**FAQ**

Direct answers, each grounded in the cited literature.

## What is PT-141?

PT-141 is the research name for bremelanotide, a synthetic cyclic peptide that activates melanocortin receptors — chiefly MC4R — in the brain. Under its approved name it is an FDA-cleared injectable for hypoactive sexual desire disorder (HSDD) in premenopausal women [5].

## What is PT-141 peptide?

It is a lactam-bridged analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), structurally related to Melanotan II but refined toward MC4R and MC3R rather than binding every melanocortin receptor [3]. "PT-141" and "bremelanotide" refer to the same molecule; PT-141 is the research-chemical framing, bremelanotide the approved pharmaceutical name.

## What does the PT-141 peptide do?

It activates central melanocortin receptors involved in sexual motivation and arousal. In placebo-controlled Phase 3 trials it produced statistically significant increases in sexual desire and reductions in desire-related distress in premenopausal women with HSDD [3]. Reported effects outside that studied population are anecdotal, not clinical evidence.

## What is PT-141 used for?

Its FDA-approved use is treatment of acquired, generalized HSDD in premenopausal women, dosed as needed by injection [5]. Use in men or postmenopausal women is off-label and has not been studied to the same standard; early Phase 2 data in men with erectile dysfunction exist but did not lead to an approval in that population [7].

## What is kisspeptin?

Kisspeptin is a family of peptides made from the KISS1 gene that acts on KISS1R, a receptor on the brain cells that release GnRH — the hormone that starts the reproductive hormone cascade. It is investigational and not approved for any use [9].

## What does kisspeptin do?

It triggers pulsatile release of GnRH from the hypothalamus, which in turn drives pituitary release of LH and FSH. Clinical studies have used it to restore LH pulsatility in women with hypothalamic amenorrhea and to safely trigger oocyte maturation during IVF, and more recent work has studied its effect on sexual desire in the brain directly [11][10][2].

## Does kisspeptin increase testosterone?

In a controlled study in healthy men, intravenous kisspeptin-10 raised serum testosterone at a higher continuous infusion rate, alongside dose-dependent increases in LH and LH pulse frequency [12]. This is a documented finding in a research setting, not a basis for self-directed use.

## How much does kisspeptin increase testosterone?

In that same study, a continuous infusion of kisspeptin-10 at 4 micrograms per kilogram per hour raised mean serum testosterone from 16.6 to 24.0 nmol/L in healthy men under supervised research conditions [12]. This is a description of a study result, not a usable or recommended protocol.

## What is Melanotan 2?

Melanotan II is a synthetic, non-selective melanocortin receptor agonist — a cyclic peptide analogue of alpha-MSH designed in the late 1980s. It is the structural ancestor of bremelanotide (PT-141) but activates all five melanocortin receptors rather than two [16].

## What is Melanotan 2 used for in research?

Early Phase 1 research studied it for skin pigmentation (tanning) and for erectile response in men, via its action on melanocortin receptors [17]. It has never advanced past small Phase 1 studies and has no FDA or other regulatory approval; it is sold outside pharmaceutical channels as a research chemical.

## How does Melanotan 2 work in the body?

It binds MC1R on skin pigment cells, driving a signaling cascade that shifts pigment production toward darker eumelanin. It also binds central MC3R and MC4R, which is the mechanism behind its studied appetite-suppressing and erectile effects [16].

## What is the melanogenesis (MC1R-cAMP-MITF) signaling cascade?

It is the pathway that produces skin darkening. Melanocortin binding to MC1R raises intracellular cAMP, which activates protein kinase A and the transcription factor MITF, which in turn upregulates tyrosinase, the enzyme that drives production of eumelanin, the darker of the two human skin pigments. This is the same receptor family — but not the same receptor — that PT-141 targets for its desire effect [16].

---

A literature index, not a clinic and not a supplier — every claim here traces to a citation, never to us.